Danielle Valletti is an assistant editor at Pharmacy Times®. She graduated from The Pennsylvania State University in May 2025 in journalism and media studies. Prior to this position, she worked as a reporter and editor for a digital news organization.
Expanding the Pharmacist’s Role in Myelofibrosis: Education, Adherence, and Access
Pharmacists play a crucial role in managing myelofibrosis, enhancing patient education, adherence, and financial navigation for optimal care.
Read More
FDA Expands Selumetinib to Children With NF1-Associated Plexiform Neurofibromas
September 10th 2025Selumetinib gains expanded FDA approval for younger pediatric patients with neurofibromatosis type 1 plexiform neurofibromas, enhancing treatment options and addressing significant disease-related challenges.
Read More
Balancing Efficacy and Safety: Navigating Dose Adjustments and Therapy Optimization in Myelofibrosis
Jessica Lewis-Gonzalez, PharmD, BCOP, discusses the management of hematologic and non-hematologic toxicities in cancer patients, emphasizing the importance of proactive monitoring and collaboration between clinicians and pharmacists.
Read More
Aficamten Emerges as a Potential First-Line Therapy in Hypertrophic Cardiomyopathy
September 10th 2025Michael Fifer, MD, discusses the Maple HCM study, which compared the cardiac myosin inhibitor Aficamten and the beta blocker Metoprolol in patients with obstructive hypertrophic cardiomyopathy (HCM).
Read More
Inside the Legislative Battle Over Oncology Patients’ Access to Critical Medications
Legislative efforts aim to improve oncology medication access, addressing transportation barriers and advocating for mail delivery from cancer clinics.
Read More
Tailoring Myelofibrosis Treatment Through JAK Inhibitors
Jessica Lewis-Gonzalez, PharmD, BCOP, discusses the challenges of managing myelofibrosis, from its heterogeneity and symptom burden to limited curative options.
Read More
CMS Mailing Restrictions and Their Impact on Oncology Care Delivery
David Eagle, MD, Chair of Legislative Affairs and Patient Advocacy, explains how CMS’s ban on community oncology practices mailing medications creates inequities with PBMs and adds burdens for vulnerable cancer patients.
Read More